While the San Francisco 49ers and other football players like Tim Tebow and the Denver Broncos are hot picks for the playoffs, so may be some penny stocks in the healthcare industry. Like the phenom quarterback of the Denver Broncos, Tim Tebow, 8 NFL teams are hoping to make it to the big game in Indianapolis while healthcare companies are taking the field in their own Super Bowl starting this Monday in a hotel in San Francisco.
The J.P. Morgan Healthcare Conference is the most important and exclusive healthcare conference of the year. As you would only need to contact a ticket scalper for a Super Bowl ticket and pay upwards of $2,000 to get in, you typically need to manage millions of dollars if you wanted to get a ticket to sit in on presentations this coming week in San Francisco and meet the CEOs of some of the largest and most innovative healthcare companies.
Investors, especially penny stock traders, are anxious to hear about how all of these healthcare companies plan on capitalizing on the millions of new patients and trillions of new dollars that are on the verge of entering the healthcare system. Presentations are scheduled from the many healthcare monopolies like of Pfizer (NYSE: PFE), Celgene (Nasdaq: CELG) and AstraZeneca (NYSE: AZN) as well as some smaller companies who will be doing the Tim Tebow genuflection demonstrations of religiosity in hopes of some big cash injections like Incyte (Nasdaq: INCY), Illumina(Nasdaq: ILMN) and NuVasive (Nasdaq: NUVA).
One company which is sure to come out a winner this week is penny stock Generex Biotechnology Corporation (OTCBB: GNBT.OB). GNBT announced last week that representatives of the Company’s wholly-owned subsidiary, Antigen Express, Inc., will be in attendance at the 2012 JPMorgan Healthcare Conference in San Francisco from January 8 through 13.
Antigen Express has already announced positive interim clinical data from our Phase 2b study in HER-2 expressing breast cancer subjects makes the time ripe for discussions with prospective partners and collaborations in respect of a Phase 3 study of the breast cancer vaccine. Representatives of Antigen Express will be available over the course of the conference to meet with prospective partners, collaborators, and investors in respect of the Antigen Express proprietary platform immunotherapeutic vaccine technologies.
The JPMorgan Healthcare Conference gives Antigen Express the opportunity to initiate discussions with multiple interested partners. GNBT product lines have applicability in diseases such as breast cancer, prostate cancer, ovarian cancer, influenza, and HIV. Efficacy of cancer vaccine AE-37 (Ii-Key/HER2 antigen hybrid) has helped to validate the Ii-Key antigen technology overall. The Ii-Key Hybrid technology allows tumor-associated or foreign antigens (like viral antigens) to potently enhance the immune system’s ability to recognize and destroy cancerous or virus infected cells bearing any of the targeted antigens as well as generate immunological memory.
Snapshot: Generex Biotechnology Corporation (OTCBB: GNBT.OB)
|Trading Symbol:||NASDAQ OTCBB: GNBT|
|Avg Vol (3 month):||1,254,380|
|Avg Vol (10 day):||938,471|
|Market Cap ($):||49.72M|
|52 Week High:||0.33|
|52 Week Low:||0.08|
|Shares Outstanding:||315.71M shares|
|Top Institutional Holder:||184,000 shares
United Capital Financial Advisers, LLC.
(as of 9/30/2011)
|Contact Information:||33 Harbour Square
Toronto, Ontario, Canada M5J 2G2Tel: (416) 364-2551
Fax: (647) 547-7104
|Investor/Analyst inquiries:||Todd Falls
Fax: (647) 547-7104
What does a cure for breast cancer mean for GNBT?
Basically, successful Phase 2b study in a cure for breast cancer has been achieved by GNBT and in moving into Phase 3 study before a product launch, Generex is “ripe” for a similar scenario as we recently saw in penny stock Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) when it was acquired for $230 million by Swiss drugmaker Roche Holding AG (OTCBB: RHHBY).
AimHighProfits.com strives to provide you with the hottest stock alerts in the market in Real-Time. We focus on stocks that trade for $5 per share or less, some as little as a few pennies with upside potential. Our goal is committed to producing and publishing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions and to inform you of the best stocks in the market before they move. Our focus is primarily on OTC stocks in the stock market today which have traditionally been ignored by Wall Street.
We have particular expertise with internet stocks, gold stocks, renewable energy stocks, biotech stocks, oil stocks and green energy stocks. There are many hot penny stock opportunities present in the OTC market every day and we seek to exploit these hot stock gains for our members before the average daytrader is made aware of them.
Aim High Profits Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. AimHighProfits.com is a wholly-owned subsidiary of Kelevra Media Innovation.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.Share